Harmony Biosciences (HRMY) vs Vera Therapeutics (VERA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Harmony Biosciences (HRMY) has outperformed Vera Therapeutics (VERA) over the past year, losing 5.0% versus a loss of 10.6%. Over five years, HRMY leads with a -13.2% price change compared with -15.2% for VERA. Harmony Biosciences is the larger company by market cap ($1.91 billion vs $1.84 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HRMY | VERA |
|---|---|---|
| Share price | $32.59 | $25.45 |
| Market cap | $1.91B | $1.84B |
| 1-day change | -1.18% | -4.86% |
| YTD return | -12.91% | -49.74% |
| 1-year return | -5.01% | -10.58% |
| 5-year return | -13.21% | -15.17% |
| P/E ratio (TTM) | 10.79 | — |
| Forward P/E | 5.37 | — |
| EPS (TTM) | $3.02 | $-5.90 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $868.45M | — |
| Revenue growth (YoY) | +21.51% | — |
| Net income (latest FY) | $158.69M | $-299.62M |
| Gross margin | 77.16% | — |
| Operating margin | 24.00% | — |
| Net margin | 18.27% | — |
| 52-week high | $43.49 | $56.05 |
| 52-week low | $25.90 | $25.08 |
| Distance from 52-week high | -25.06% | -54.59% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +47.53% | +180.39% |
| Average volume | 1.01M | 1.95M |
| Shares outstanding | 58.72M | 72.30M |
| Employees | 293 | 362 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Harmony Biosciences
HRMY stock →Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Health Care · Biotechnology: Pharmaceutical Preparations · 293 employees
About Vera Therapeutics
VERA stock →Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 362 employees
HRMY vs VERA FAQ
Which is bigger, Harmony Biosciences or Vera Therapeutics?
Harmony Biosciences (HRMY) is larger, with a market capitalization of $1.91B compared with $1.84B for Vera Therapeutics (VERA).
Which stock has performed better over the past year, HRMY or VERA?
HRMY returned -5.01% over the past 12 months, compared with -10.58% for VERA (price return, excluding dividends). Past performance does not predict future results.
Are Harmony Biosciences and Vera Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.